Discover the PCG Difference!
Interesting seminar regarding Nonalcoholic Steatohepatitis (NASH)
It was great to attend the DANSK BIOTEK and Gupra event on November 23rd, we were very thankful for the very interesting seminar regarding Nonalcoholic Steatohepatitis (NASH)!
We can conclude that there is a substantial unmet need for effective treatment of NASH. Also NASH is very difficult to identify and many people have it without knowing it.
Dr. Philip Just Larsen at Sanofi-Aventis concluded that the NASH population is expected to grow by 45% within EU until 2030. Since there are no therapies licensed today or NASH, this is a big opportunity for any company willing to join the “NASH frenzy”!